[EN] DUAL NAV1.2/5HT2A INHIBITORS FOR TREATING CNS DISORDERS<br/>[FR] INHIBITEURS DOUBLES DE NAV1.2/5HT2A POUR TRAITER DES TROUBLES DU SNC
申请人:SUNOVION PHARMACEUTICALS INC
公开号:WO2018026371A1
公开(公告)日:2018-02-08
Compounds of formula I: I are disclosed, as are pharmaceutical compositions containing such compounds. Methods of treating neurological or psychiatric disorders in a patient in need are also disclosed. Such disorders include depression, bipolar disorder, pain, schizophrenia, obsessive compulsive disorder, addiction, social disorder, attention deficit hyperactivity disorder, an anxiety disorder, autism, a cognitive impairment, or a neuropsychiatric symptom such as apathy, depression, anxiety, psychosis, aggression, agitation, impulse control disorders, and sleep disorders in neurological disorders such as Alzheimer's and Parkinson's diseases.
AZEPANE DERIVATIVES AND METHODS OF TREATING HEPATITIS B INFECTIONS
申请人:Novira Therapeutics, Inc.
公开号:US20150197533A1
公开(公告)日:2015-07-16
Provided herein are compounds useful for the treatment of HBV infection in a subject in need thereof, pharmaceutical compositions thereof, and methods of inhibiting, suppressing, or preventing HBV infection in the subject.
Expedient Access to Underexplored Chemical Space: Deoxygenative C(sp<sup>3</sup>)–C(sp<sup>3</sup>) Cross-Coupling
作者:William L. Lyon、David W. C. MacMillan
DOI:10.1021/jacs.3c01488
日期:——
bond-forming cross-couplings remains underexplored. Herein we report an N-heterocyclic carbene (NHC)-mediated deoxygenative alkylation of alcohols and alkyl bromides via nickel–metallaphotoredox catalysis. This C(sp3)–C(sp3) cross-coupling exhibits a broad scope and is capable of forming bonds between two secondary carbon centers, a longstanding challenge in the field. Highlystrained three-dimensional